Agile Therapeutics

Executive Summary

Agile Therapeutics is a women's healthcare company specializing in innovative contraceptive products, anchored by its proprietary Skinfusion® transdermal patch technology. Its lead product, Twirla® (levonorgestrel/ethinyl estradiol), is an FDA-approved once-weekly contraceptive patch that offers a convenient alternative to daily pills. The company targets the significant unmet need in the contraceptive market for non-oral options with improved adherence. Despite its innovative platform, Agile faces challenges in commercial adoption, including competition from established oral contraceptives, long-acting reversible contraceptives (LARCs), and other patches. As a private company, it has limited public financial disclosures, but its focused pipeline suggests potential for strategic partnerships or label expansions to drive growth.

Upcoming Catalysts (preview)

• Q4 2026Twirla label expansion to include adolescents or extended use60% success
• H1 2027Strategic partnership or licensing deal for Skinfusion platform50% success
• TBDNew product candidate entering clinical trials (e.g., hormone replacement therapy patch)40% success